
Vor Biopharma Inc.: shareholders and insiders
Price
$19.19
November 20, 2026Market cap $1.2B
What Ploutos Investor adds for Vor Biopharma
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- RA Capital Management, L.P.with 3 more personsShare of class19.9%
- Reprogrammed Interchange LLCwith 1 more personShare of class17.6%
- FMRwith 1 more personShare of class10.7%
- TCG Crossover GP II, LLCwith 4 more personsShare of class10.5%
- ForGrowth III PA B.V.with 2 more personsShare of class9.99%
- Venrock Healthcare Capital Partners III, L.P.with 6 more personsShare of class9.90%
- Verve Capital LimitedShare of class6.30%
- BlackRock, Inc.Share of class5.70%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P.with 3 more persons | 19.9% | 12.94M | Jul 21, 202615 filings since Dec 30, 2024 | 13D/A | |
| Reprogrammed Interchange LLCwith 1 more person | 17.6% | 1.20M | Oct 17, 20259 filings since Jan 7, 2025 | 13D/A | |
| FMRwith 1 more person | 10.7% | 6.32M | Nov 5, 20269 filings since Feb 12, 2025 | 13G/A | |
| TCG Crossover GP II, LLCwith 4 more persons | 10.5% | 5.67M | Apr 1, 2026 | 13G | |
| ForGrowth III PA B.V.with 2 more persons | 9.99% | 10.24M | Dec 23, 20252 filings since Sep 23, 2025 | 13D | |
| Venrock Healthcare Capital Partners III, L.P.with 6 more persons | 9.90% | 5.68M | Aug 14, 20264 filings since Sep 25, 2025 | 13G/A | |
| Verve Capital Limited | 6.30% | 3.41M | Aug 13, 20264 filings since Sep 26, 2025 | 13G/A | |
| BlackRock, Inc. | 5.70% | 3.10M | Jul 30, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
RA Capital Management, L.P.19.9%From the filing of Jul 21, 2026
Item 4 of the Statement is hereby amended and supplemented as follows: Effective July 6, 2026, Andrew Levin resigned from the Board of Directors of the Issuer.
From the filing of Jul 21, 2026Reprogrammed Interchange LLC17.6%From the filing of Oct 17, 2025
Item 4 of Schedule 13D is hereby amended and supplemented as follows: From October 15, 2025 through October 16, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 71,655 shares on October 15, 2025, at a weighted average per share sale price of $31.9196. 2. 2,021 shares on October 16, 2025, at a weighted average per share sale price of $30.4548.
From the filing of Oct 17, 2025ForGrowth III PA B.V.10.0%From the filing of Dec 23, 2025
The Reporting Persons acquired their shares of Common Stock as an investment in the ordinary course of business. On December 18, 2025, Wouter Joustra, a General Partner at Forbion Capital, was appointed to the Issuer's board of directors. The Reporting Persons, either directly or indirectly through Mr. Joustra, may engage in discussions from time to time with the Issuer's board of directors, the Issuer's management or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing of the shares or other securities of the Issuer; (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy or capitalization; or (iii)…
From the filing of Dec 23, 2025
Fell to 5% or less (5)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+210%
- Millennium Mgmt (Englander)In the quarter+132%
- D.E. ShawIn the quarter+345%
- Renaissance TechnologiesIn the quarter
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 343.0K | $6.5M | 0.01% | |
| Citadel Advisors (Griffin) | 498.0K | +210% | $9.5M | 0.01% |
| Millennium Mgmt (Englander) | 991.5K | +132% | $19M | 0.01% |
| D.E. Shaw | 243.2K | +345% | $4.6M | 0.00% |
| Renaissance Technologies | – | – | 0.00% | |
| AQR Capital | 175.8K | $3.4M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.1% of its shares outstanding were held short, -4.7% since the report before.
- Shares held short
- 7.45M
- 12.1%
- Since the report before7.81M on Sep 30, 2026
- -4.7%
- 9.0
- 830.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 88%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 2.75M
- Nov 15, 2023: Shares held short 2.83M
- Nov 30, 2023: Shares held short 2.88M
- Dec 15, 2023: Shares held short 2.76M
- Dec 29, 2023: Shares held short 2.94M
- Jan 12, 2024: Shares held short 2.96M
- Jan 31, 2024: Shares held short 2.92M
- Feb 15, 2024: Shares held short 2.99M
- Feb 29, 2024: Shares held short 2.98M
- Mar 15, 2024: Shares held short 3.07M
- Mar 28, 2024: Shares held short 3.24M
- Apr 15, 2024: Shares held short 3.39M
- Apr 30, 2024: Shares held short 3.68M
- May 15, 2024: Shares held short 3.49M
- May 31, 2024: Shares held short 3.57M
- Jun 14, 2024: Shares held short 3.80M
- Jun 28, 2024: Shares held short 2.83M
- Jul 15, 2024: Shares held short 1.86M
- Jul 31, 2024: Shares held short 1.80M
- Aug 15, 2024: Shares held short 1.66M
- Aug 30, 2024: Shares held short 1.56M
- Sep 13, 2024: Shares held short 2.54M
- Sep 30, 2024: Shares held short 1.97M
- Oct 15, 2024: Shares held short 1.71M
- Oct 31, 2024: Shares held short 1.37M
- Nov 15, 2024: Shares held short 1.55M
- Nov 29, 2024: Shares held short 1.41M
- Dec 13, 2024: Shares held short 1.30M
- Dec 31, 2024: Shares held short 1.23M
- Jan 15, 2025: Shares held short 1.15M
- Jan 31, 2025: Shares held short 1.27M
- Feb 14, 2025: Shares held short 1.44M
- Feb 28, 2025: Shares held short 1.45M
- Mar 14, 2025: Shares held short 1.33M
- Mar 31, 2025: Shares held short 1.33M
- Apr 15, 2025: Shares held short 1.31M
- Apr 30, 2025: Shares held short 1.11M
- May 15, 2025: Shares held short 2.76M
- May 30, 2025: Shares held short 4.19M
- Jun 13, 2025: Shares held short 3.22M
- Jun 30, 2025: Shares held short 18.05M
- Jul 15, 2025: Shares held short 14.38M
- Jul 31, 2025: Shares held short 18.57M
- Aug 15, 2025: Shares held short 18.41M
- Aug 29, 2025: Shares held short 19.78M
- Sep 15, 2025: Shares held short 22.02M
- Sep 30, 2025: Shares held short 1.35M
- Oct 15, 2025: Shares held short 1.24M
- Oct 31, 2025: Shares held short 911.6K
- Nov 14, 2025: Shares held short 294.6K
- Nov 28, 2025: Shares held short 226.4K
- Dec 15, 2025: Shares held short 1.94M
- Dec 31, 2025: Shares held short 2.27M
- Jan 15, 2026: Shares held short 2.19M
- Jan 30, 2026: Shares held short 2.55M
- Feb 13, 2026: Shares held short 3.18M
- Feb 27, 2026: Shares held short 3.39M
- Mar 13, 2026: Shares held short 3.42M
- Mar 31, 2026: Shares held short 5.69M
- Apr 15, 2026: Shares held short 4.71M
- Apr 30, 2026: Shares held short 4.96M
- May 15, 2026: Shares held short 4.60M
- May 29, 2026: Shares held short 4.82M
- Jun 15, 2026: Shares held short 5.95M
- Jun 30, 2026: Shares held short 7.74M
- Jul 15, 2026: Shares held short 7.29M
- Jul 31, 2026: Shares held short 7.25M
- Aug 14, 2026: Shares held short 7.35M
- Aug 31, 2026: Shares held short 7.67M
- Sep 15, 2026: Shares held short 7.90M
- Sep 30, 2026: Shares held short 7.81M
- Oct 15, 2026: Shares held short 7.45M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading57.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 57.1% of the shares in the reported trades were short sales, against 50.9% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 57.1%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 50.9%
- Change
- +6.2 pts
- Short sales a dayon average, of 251.7K shares
- 143.7K
- More than atof 3,666 US-listed companies, same days
- 74%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 60.6%
- Oct 15, 2026: Short sales 58.6%
- Oct 16, 2026: Short sales 52.6%
- Oct 19, 2026: Short sales 48%
- Oct 20, 2026: Short sales 32.8%
- Oct 21, 2026: Short sales 36.4%
- Oct 22, 2026: Short sales 42%
- Oct 23, 2026: Short sales 37.3%
- Oct 26, 2026: Short sales 57.2%
- Oct 27, 2026: Short sales 46.9%
- Oct 28, 2026: Short sales 41.8%
- Oct 29, 2026: Short sales 73.7%
- Oct 30, 2026: Short sales 57.1%
- Nov 2, 2026: Short sales 61.6%
- Nov 3, 2026: Short sales 52.6%
- Nov 4, 2026: Short sales 71.9%
- Nov 5, 2026: Short sales 64%
- Nov 6, 2026: Short sales 39.1%
- Nov 9, 2026: Short sales 36.3%
- Nov 10, 2026: Short sales 47.7%
- Nov 11, 2026: Short sales 68.6%
- Nov 12, 2026: Short sales 66.8%
- Nov 13, 2026: Short sales 52%
- Nov 16, 2026: Short sales 58.6%
- Nov 17, 2026: Short sales 56.1%
- Nov 18, 2026: Short sales 69%
- Nov 19, 2026: Short sales 64.8%
- Nov 20, 2026: Short sales 59.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.30%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.26%
- IWCiShares Micro-Cap ETFWeight in the fund0.15%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- VHTVanguard Health Care Index FundWeight in the fund0.01%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.00%
13 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 37
- Q4 2025: Managers 55
- Q1 2026: Managers 80
- Q2 2026: Managers 102
Institutional investors by quarter
The fund managers holding VOR, quarter by quarter, from Q1 2021 to Q2 2025, 18 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 102 managers held 49.35M shares, worth $909M. During the quarter 38 opened a position, 17 closed one, 33 added and 19 trimmed.
The largest holders, Q2 2026
- TCG Crossover ManagementIn the quarter
- FMRIn the quarter+220%
- Fcpm Iii Services B.v.In the quarter
- BlackRockIn the quarter+336%
- Venrock AdviserIn the quarter
- State StreetIn the quarter+134%
- Frazier Life Sciences ManagementIn the quarter
- Ra Capital ManagementIn the quarter-56%
- Vanguard Capital ManagementIn the quarter+45%
- Caligan PartnersIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| TCG Crossover Management | 5.67M | $104M | |
| FMR | 4.93M | +220% | $91M |
| Fcpm Iii Services B.v. | 4.12M | $76M | |
| BlackRock | 3.47M | +336% | $64M |
| Venrock Adviser | 3.04M | $56M | |
| State Street | 2.62M | +134% | $48M |
| Frazier Life Sciences Management | 2.54M | $47M | |
| Ra Capital Management | 2.40M | -56% | $44M |
| Vanguard Capital Management | 2.08M | +45% | $38M |
| Caligan Partners | 1.93M | $35M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Vor Biopharma's filings show?
Who buys and sells is one part of Vor Biopharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold VOR?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $19M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.